Logo image of EOLS

EVOLUS INC (EOLS) Stock Fundamental Analysis

NASDAQ:EOLS - US30052C1071 - Common Stock

7.51 USD
-0.01 (-0.13%)
Last: 8/29/2025, 10:34:54 AM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to EOLS. EOLS was compared to 193 industry peers in the Pharmaceuticals industry. EOLS has a bad profitability rating. Also its financial health evaluation is rather negative. EOLS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EOLS has reported negative net income.
In the past year EOLS has reported a negative cash flow from operations.
EOLS had negative earnings in each of the past 5 years.
EOLS had a negative operating cash flow in each of the past 5 years.
EOLS Yearly Net Income VS EBIT VS OCF VS FCFEOLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

EOLS has a Return On Assets (-27.10%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -27.1%
ROE N/A
ROIC N/A
ROA(3y)-32.04%
ROA(5y)-38.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EOLS Yearly ROA, ROE, ROICEOLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

EOLS has a Gross Margin of 66.63%. This is in the better half of the industry: EOLS outperforms 74.09% of its industry peers.
EOLS's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for EOLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.76%
GM growth 5Y-2.34%
EOLS Yearly Profit, Operating, Gross MarginsEOLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

3

2. Health

2.1 Basic Checks

EOLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
EOLS has more shares outstanding than it did 1 year ago.
EOLS has more shares outstanding than it did 5 years ago.
EOLS has a better debt/assets ratio than last year.
EOLS Yearly Shares OutstandingEOLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
EOLS Yearly Total Debt VS Total AssetsEOLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -1.72, we must say that EOLS is in the distress zone and has some risk of bankruptcy.
EOLS has a Altman-Z score (-1.72) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.72
ROIC/WACCN/A
WACC11.16%
EOLS Yearly LT Debt VS Equity VS FCFEOLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.27 indicates that EOLS has no problem at all paying its short term obligations.
EOLS has a Current ratio (2.27) which is in line with its industry peers.
EOLS has a Quick Ratio of 1.86. This is a normal value and indicates that EOLS is financially healthy and should not expect problems in meeting its short term obligations.
EOLS's Quick ratio of 1.86 is in line compared to the rest of the industry. EOLS outperforms 44.04% of its industry peers.
Industry RankSector Rank
Current Ratio 2.27
Quick Ratio 1.86
EOLS Yearly Current Assets VS Current LiabilitesEOLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for EOLS have decreased strongly by -21.95% in the last year.
Looking at the last year, EOLS shows a quite strong growth in Revenue. The Revenue has grown by 17.15% in the last year.
The Revenue has been growing by 50.14% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-21.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-475%
Revenue 1Y (TTM)17.15%
Revenue growth 3Y38.74%
Revenue growth 5Y50.14%
Sales Q2Q%3.7%

3.2 Future

EOLS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 62.30% yearly.
EOLS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.28% yearly.
EPS Next Y-96.86%
EPS Next 2Y85.81%
EPS Next 3Y82.31%
EPS Next 5Y62.3%
Revenue Next Year11.78%
Revenue Next 2Y20.3%
Revenue Next 3Y23.39%
Revenue Next 5Y22.28%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
EOLS Yearly Revenue VS EstimatesEOLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
EOLS Yearly EPS VS EstimatesEOLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

EOLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 20.68, EOLS is valued on the expensive side.
Compared to the rest of the industry, the Price/Forward Earnings ratio of EOLS indicates a somewhat cheap valuation: EOLS is cheaper than 75.65% of the companies listed in the same industry.
EOLS is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.78, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 20.68
EOLS Price Earnings VS Forward Price EarningsEOLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EOLS Per share dataEOLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

EOLS's earnings are expected to grow with 82.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y85.81%
EPS Next 3Y82.31%

More info and screens

0

5. Dividend

5.1 Amount

EOLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOLUS INC

NASDAQ:EOLS (8/29/2025, 10:34:54 AM)

7.51

-0.01 (-0.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners78.75%
Inst Owner Change6.75%
Ins Owners0.96%
Ins Owner Change0.77%
Market Cap485.82M
Analysts86.15
Price Target19.82 (163.91%)
Short Float %23.67%
Short Ratio9.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-54.87%
Min EPS beat(2)-108.79%
Max EPS beat(2)-0.95%
EPS beat(4)1
Avg EPS beat(4)-41.86%
Min EPS beat(4)-108.79%
Max EPS beat(4)3.2%
EPS beat(8)4
Avg EPS beat(8)-24.08%
EPS beat(12)8
Avg EPS beat(12)-14.96%
EPS beat(16)10
Avg EPS beat(16)-10.12%
Revenue beat(2)0
Avg Revenue beat(2)-12.02%
Min Revenue beat(2)-17.08%
Max Revenue beat(2)-6.96%
Revenue beat(4)0
Avg Revenue beat(4)-7.23%
Min Revenue beat(4)-17.08%
Max Revenue beat(4)-1.09%
Revenue beat(8)2
Avg Revenue beat(8)-2.4%
Revenue beat(12)4
Avg Revenue beat(12)-2.35%
Revenue beat(16)6
Avg Revenue beat(16)-1.09%
PT rev (1m)-15.53%
PT rev (3m)-17.68%
EPS NQ rev (1m)-350%
EPS NQ rev (3m)-751.35%
EPS NY rev (1m)-289.11%
EPS NY rev (3m)-271.15%
Revenue NQ rev (1m)-19.67%
Revenue NQ rev (3m)-19.75%
Revenue NY rev (1m)-14.55%
Revenue NY rev (3m)-14.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 20.68
P/S 1.75
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.5
EYN/A
EPS(NY)0.36
Fwd EY4.84%
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS4.3
BVpS-0.29
TBVpS-1.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.1%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.63%
FCFM N/A
ROA(3y)-32.04%
ROA(5y)-38.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.76%
GM growth 5Y-2.34%
F-Score2
Asset Turnover1.21
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 97.78%
Cap/Sales 2.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.27
Quick Ratio 1.86
Altman-Z -1.72
F-Score2
WACC11.16%
ROIC/WACCN/A
Cap/Depr(3y)62.29%
Cap/Depr(5y)49.76%
Cap/Sales(3y)1.53%
Cap/Sales(5y)2.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-475%
EPS Next Y-96.86%
EPS Next 2Y85.81%
EPS Next 3Y82.31%
EPS Next 5Y62.3%
Revenue 1Y (TTM)17.15%
Revenue growth 3Y38.74%
Revenue growth 5Y50.14%
Sales Q2Q%3.7%
Revenue Next Year11.78%
Revenue Next 2Y20.3%
Revenue Next 3Y23.39%
Revenue Next 5Y22.28%
EBIT growth 1Y-35.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year823.46%
EBIT Next 3Y320.78%
EBIT Next 5Y182.86%
FCF growth 1Y23.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.78%
OCF growth 3YN/A
OCF growth 5YN/A